GlaxoSmithKline has confirmed it will face a challenging 2019 as generics of its big-selling Advair drug finally reach the US, as it continues the transformation of its business. The FDA approved ...

GlaxoSmithKline is expecting flat earnings this year, having earlier forecast a decline, as rising sales of new drugs have helped offset the impact of generics on its Advair blockbuster in the US.

Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is ... twice daily from a Diskus™ inhaler for a 4-week ...